Nancy A.  Grygiel net worth and biography

Nancy Grygiel Biography and Net Worth

SVP of Amgen
Nancy Grygiel serves as senior vice president and chief compliance officer, responsible for Amgen’s Compliance, Global Privacy, and Trade organization. Grygiel joined Amgen in 2015 as vice president of Compliance, responsible for overseeing Amgen’s healthcare and anti-corruption compliance programs in all markets. In addition, Grygiel has been accountable for reporting on the status and effectiveness of the program’s elements, and ongoing activities to Amgen’s CEO operating teams, and to the company’s Corporate Responsibility and Compliance Committee (CRCC), on an ongoing basis.

Prior to joining Amgen, Grygiel served as vice president, Compliance, at Allergan. In that role, she was responsible for the implementation and execution of the corporate compliance program’s global strategy. In addition, Grygiel led cross-functional compliance-related efforts and served as an advisor to the corporate audit function on Foreign Corrupt Practices Act and other applicable in-country healthcare laws and regulations.

Prior to her time at Allergan, Grygiel held positions of increasing responsibility at Mylan Pharmaceuticals, where she developed and established the export controls and international compliance program, as a result of the company’s rapid global expansion in 2007.

Earlier in her career, Grygiel worked in the legal field with a focus on international laws, transnational business transactions and export-control laws. She also held in-house legal roles within the telecommunications industry in her home country of Argentina.

Grygiel has a law degree from Buenos Aires University and a Master of Laws degree (LL.M) from Georgetown University Law Center.

What is Nancy A. Grygiel's net worth?

The estimated net worth of Nancy A. Grygiel is at least $2.95 million as of May 3rd, 2024. Ms. Grygiel owns 9,883 shares of Amgen stock worth more than $2,951,261 as of June 15th. This net worth evaluation does not reflect any other assets that Ms. Grygiel may own. Learn More about Nancy A. Grygiel's net worth.

How do I contact Nancy A. Grygiel?

The corporate mailing address for Ms. Grygiel and other Amgen executives is ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA, 91320. Amgen can also be reached via phone at (805) 447-1000 and via email at [email protected]. Learn More on Nancy A. Grygiel's contact information.

Has Nancy A. Grygiel been buying or selling shares of Amgen?

During the last ninety days, Nancy A. Grygiel has sold $662,811.53 in Amgen stock. Most recently, Nancy A. Grygiel sold 2,117 shares of the business's stock in a transaction on Friday, May 3rd. The shares were sold at an average price of $313.09, for a transaction totalling $662,811.53. Following the completion of the sale, the senior vice president now directly owns 9,883 shares of the company's stock, valued at $3,094,268.47. Learn More on Nancy A. Grygiel's trading history.

Who are Amgen's active insiders?

Amgen's insider roster includes Robert Bradway (Chairman & CEO), Robert Eckert (Director), Murdo Gordon (EVP), Jonathan Graham (EVP), Peter Griffith (Exec. VP & CFO ), Nancy Grygiel (SVP), Nancy Grygiel (SVP), Ronald Sugar (Director), Ronald Sugar (Director), and R Williams (Director). Learn More on Amgen's active insiders.

Are insiders buying or selling shares of Amgen?

During the last year, Amgen insiders bought shares 1 times. They purchased a total of 1,764,705 shares worth more than $29,999,985.00. During the last year, insiders at the medical research company sold shares 4 times. They sold a total of 23,771 shares worth more than $6,471,488.35. The most recent insider tranaction occured on May, 3rd when SVP Nancy A Grygiel sold 2,117 shares worth more than $662,811.53. Insiders at Amgen own 0.7% of the company. Learn More about insider trades at Amgen.

Information on this page was last updated on 5/3/2024.

Nancy A. Grygiel Insider Trading History at Amgen

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/3/2024Sell2,117$313.09$662,811.539,883View SEC Filing Icon  
12/4/2023Sell2,096$273.03$572,270.8810,874View SEC Filing Icon  
11/8/2022Sell545$293.54$159,979.3013,009View SEC Filing Icon  
5/11/2021Sell2,500$252.51$631,275.0014,961View SEC Filing Icon  
See Full Table

Nancy A. Grygiel Buying and Selling Activity at Amgen

This chart shows Nancy A Grygiel's buying and selling at Amgen by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Amgen Company Overview

Amgen logo
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
Read More

Today's Range

Now: $298.62
Low: $295.90
High: $299.74

50 Day Range

MA: $292.77
Low: $262.75
High: $319.04

2 Week Range

Now: $298.62
Low: $218.44
High: $329.72

Volume

1,711,994 shs

Average Volume

2,756,564 shs

Market Capitalization

$160.19 billion

P/E Ratio

42.66

Dividend Yield

2.99%

Beta

0.6